2132.5000 4.80 (0.23%)
NSE Sep 12, 2025 15:31 PM
Volume: 615.4K
 

HDFC Securities
In 3QFY17, GNPs US business more than doubled to Rs 12.3bn, driving 41%YoY growth in overall top line. This was largely driven by sales of gZetia under 180 day?s exclusivity. However, bumper sales are likely to stay only till 1QFY18, post which gZetia will become more competitive market for GNP.
Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
More from Glenmark Pharmaceuticals Ltd.
Recommended